Patient surveys
Prospective, virtual, real-world data study in adults and adolescents ≥12 years with symptoms suggestive of acute rhinosinusitis (SinARv)
Germany
EU PAS number:
EUPAS1000000526
First published:
04/04/2025
StudyOngoing
Concept Elicitation Qualitative Study: Migraine Patient Experiences with Zavegepant
United States
EU PAS number:
EUPAS1000000442
First published:
17/04/2025
StudyOngoing
Patient characteristics, Adherence, and Clinical Outcomes among People Living with HIV (PLWH), Initiating Cabotegravir + Rilpivirine LA Regimen in the OPERA Cohort
United States
EU PAS number:
EUPAS1000000427
First published:
04/01/2025
StudyOngoing
Observational Cohort Study of Lasmiditan Exposure and Motor Vehicle Accidents in the United States (MI DRIVE) H8H-MC-B006
United States
EU PAS number:
EUPAS1000000347
First published:
20/11/2024
StudyPlanned
Implementation of controlled access to and distribution of medicinal products in European Union (CONTROL-EU)
Austria
Greece
Latvia
Netherlands
Portugal
Slovenia
Spain
Sweden
EU PAS number:
EUPAS1000000313
First published:
14/04/2025
StudyPlanned
Describing Real-World Rimegepant Utilization Patterns and Understanding Perceptions of Migraine Treatment Optimization from the Perspectives of Patients
United States
EU PAS number:
EUPAS1000000232
First published:
23/01/2025
StudyOngoing
LOOK-UP: Active pharmacovigilance study of the medicine Rinvoq™ (upadacitinib)
Portugal
EU PAS number:
EUPAS1000000227
First published:
14/03/2025
StudyFinalised
Cross-sectional study to assess the effectiveness of the patients’ alert card to inform on the risk of differentiation syndrome in AML patients treated with TIBSOVO® (Ivosidenib) (IMPACTA)
France
Germany
Netherlands
EU PAS number:
EUPAS1000000190
First published:
06/06/2024
StudyOngoing
Real-world treatment patterns and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line (1L) axitinib + pembrolizumab therapy
United States
EU PAS number:
EUPAS1000000104
First published:
15/04/2025
StudyOngoing
TAK-633-4008: Quantitative Testing of Patient and Prescriber Knowledge, Attitudes, and Behavior about GATTEX (Teduglutide) for Injection Safety and Use Information (GATTEX KAB)
United States
EU PAS number:
EUPAS48716
First published:
06/12/2024
StudyOngoing